VLDLR Antibody (6A6): sc-18824

VLDLR Antibody (6A6) is a mouse monoclonal IgG1 antibody that detects the VLDLR protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. VLDLR monoclonal antibody (6A6) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. The VLDLR protein, or very low density lipoprotein receptor, is a crucial member of the LDL receptor gene family, which plays a significant role in lipid metabolism and neuronal development. VLDLR is primarily located in the brain, heart, skeletal muscle, and adipose tissue, where VLDLR is involved in mediating the interaction between extracellular Reelin and cytosolic mDab1 (mammalian disabled protein). This interaction is essential for activating a tyrosine kinase pathway that regulates the migration of neurons along the radial glial fiber network during brain development, highlighting VLDLR′s importance in both neurodevelopmental processes and lipid homeostasis. Additionally, VLDLR associates with receptor-associated protein (RAP) during folding, which is critical for the proper secretion of VLDLR′s extracellular region, further emphasizing VLDLR′s functional significance in cellular processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

VLDLR Antibody (6A6) References:

1. Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2.  |  Trommsdorff, M., et al. 1999. Cell. 97: 689-701. PMID: 10380922
2. 39-kDa receptor-associated protein (RAP) facilitates secretion and ligand binding of extracellular region of very-low-density-lipoprotein receptor: implications for a distinct pathway from low-density-lipoprotein receptor.  |  Sato, A., et al. 1999. Biochem J. 341 (Pt 2): 377-83. PMID: 10393096
3. The carboxyl-terminal domain of receptor-associated protein facilitates proper folding and trafficking of the very low density lipoprotein receptor by interaction with the three amino-terminal ligand-binding repeats of the receptor.  |  Savonen, R., et al. 1999. J Biol Chem. 274: 25877-82. PMID: 10464330
4. Mouse very low-density lipoprotein receptor (VLDLR): gene structure, tissue-specific expression and dietary and developmental regulation.  |  Tiebel, O., et al. 1999. Atherosclerosis. 145: 239-51. PMID: 10488949
5. Functional domains of the very low density lipoprotein receptor: molecular analysis of ligand binding and acid-dependent ligand dissociation mechanisms.  |  Mikhailenko, I., et al. 1999. J Cell Sci. 112 (Pt 19): 3269-81. PMID: 10504332
6. Reelin is a ligand for lipoprotein receptors.  |  D'Arcangelo, G., et al. 1999. Neuron. 24: 471-9. PMID: 10571240
7. Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation.  |  Hiesberger, T., et al. 1999. Neuron. 24: 481-9. PMID: 10571241
8. Very low density lipoprotein receptor regulates dendritic spine formation in a RasGRF1/CaMKII dependent manner.  |  DiBattista, AM., et al. 2015. Biochim Biophys Acta. 1853: 904-17. PMID: 25644714
9. Very Low Density Lipoprotein Receptor Sequesters Lipopolysaccharide Into Adipose Tissue During Sepsis.  |  Shimada, T., et al. 2020. Crit Care Med. 48: 41-48. PMID: 31651422
10. Soluble very low-density lipoprotein receptor (sVLDLR) inhibits fibrosis in neovascular age-related macular degeneration.  |  Ma, X., et al. 2021. FASEB J. 35: e22058. PMID: 34820908
11. Very-low-density lipoprotein receptor-enhanced lipid metabolism in pancreatic stellate cells promotes pancreatic fibrosis.  |  Yang, X., et al. 2022. Immunity. 55: 1185-1199.e8. PMID: 35738281
12. Thrombospondin 1 and Reelin act through Vldlr to regulate cardiac growth and repair.  |  Pei, L., et al. 2024. Basic Res Cardiol. 119: 169-192. PMID: 38147128

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-VLDLR Antibody (6A6) has 50 citations in a variety of scientific publications.

Primary antibodies like Anti-VLDLR Antibody (6A6) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

VLDLR Antibody (6A6) Specifications

Alternate Product Name: VLDL Receptor

Product Clone Name: 6A6

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ lambda light chain

Amino Acids:

Epitope Target: VLDLR

Epitope Species: rat

Product Reactivity/Detection: VLDLR

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P)

Vialing Information: Each vial contains 200 µg IgG₁ lambda light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 50 citations in various scientific publications

Available Conjugates/Forms for VLDLR Antibody (6A6): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin